CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Lifestyle Modifications for Preventing and Treating Heart Failure Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Clinical TrialNovember 10, 2018

JOURNAL:N Engl J Med. Article Link

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

SD Wiviott,I Raz,DECLARE–TIMI 58 Investigators. Keywords: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Smoking

FULL TEXT PDF